Status:
UNKNOWN
Butorphanol Mitigate Emergence Agitation in Patients Undergoing Functional Endoscopic Sinus Surgery
Lead Sponsor:
RenJi Hospital
Conditions:
Agitation
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Emergence agitation is one of the common postoperative complications after functional endoscopic sinus surgery（FESS). The objective of present study is to explore the effectiveness of butorphanol in t...
Detailed Description
Butorphanol is a mixed agonist-antagonist opioid with strong κappa-receptor agonist and weak mu-receptor antagonist activity. It is commonly used for the management of cancer, postoperative, gynecolog...
Eligibility Criteria
Inclusion
- Age \>=18 years,\<=65years;
- height 150-180 cm;
- weight 55-80 kg;
- Signed the inform consent
- American Society of Anesthesiologists classification I to II
- Select to functional endoscopic sinus surgery
Exclusion
- Existing cerebral disease, or have a history of neurological and psychiatric diseases including Alzheimer Disease, stroke, epilepsy and psychosis;
- Several audition or vision disorder;
- Unwillingness to comply with the protocol or procedures.
- Can not communicated with Chinese Mandarin
- Existing bradycardiac arrhythmia（Heart rate \<60 bpm for any reasons）
- Existing gastrointestinal ulcer
- Existing urinary incontinence
- Existing asthma or chronic obstructive pulmonary disease
- Allegory to Butorphanol
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT03398759
Start Date
February 1 2018
End Date
December 31 2020
Last Update
March 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, Shanghai Municipality, China, 200127